Viking Therapeutics announced the pricing of its public offerings, raising up to $275 million through common stock and convertible senior notes. The company plans to use the proceeds to advance clinical development and commercialization of its obesity and metabolic disease drug candidates, including VK2735 and VK3019. The convertible notes carry a 2% interest rate and mature in 2032, with options for early conversion and redemption. This funding supports Viking's goal to develop innovative therapies for obesity and related conditions.
Viking Therapeutics' recent financing news is presented with Pluang's Health sector market data for context. As of Sep 24, 2026 16:31 WIB, 31 of 100 Health-sector US stocks rose while 66 fell. Notable movers include HRTX at USD 0.30 (+3.06%), WGS at USD 82.69 (-2.95%), and MRNA at USD 176.90 (-2.86%).
XRP showed a potential bullish inverse head-and-shoulders pattern with a key resistance neckline near $1.57 and further resistance around $1.60. A decisive and sustained break above these levels is needed to strengthen the bullish case and target $2....
Google announced a new initiative partnering with veterans organizations to help 25,000 veterans, service members, and military spouses enter skilled trades. This effort addresses a nationwide shortage of skilled trade workers driven by increased dem...
OS Therapies announced that the World Health Organization has approved 'Herlystic' as the brand name for its gene-edited cancer immunotherapy OST-HER2. With both the proprietary and nonproprietary names approved, the company is set to begin regulator...
XRP climbed from around $1.27 to test resistance between $1.61 and $1.70 but faced selling pressure that pushed it back to about $1.47. The token is currently testing a critical support zone around $1.42-$1.45, which overlaps with previous resistance...
Ventripoint Diagnostics has successfully completed its annual quality and regulatory audits, including the Medical Device Single Audit Program, ISO 13485:2016, and the EU Medical Device Regulation. These audits confirm the effectiveness of Ventripoin...
